GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Cyclically Adjusted Revenue per Share

Zydus Lifesciences (BOM:532321) Cyclically Adjusted Revenue per Share : ₹171.08 (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zydus Lifesciences's adjusted revenue per share for the three months ended in Mar. 2025 was ₹62.476. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹171.08 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Zydus Lifesciences's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zydus Lifesciences was 9.60% per year. The lowest was 9.10% per year. And the median was 9.50% per year.

As of today (2025-05-30), Zydus Lifesciences's current stock price is ₹929.85. Zydus Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹171.08. Zydus Lifesciences's Cyclically Adjusted PS Ratio of today is 5.44.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zydus Lifesciences was 7.98. The lowest was 2.07. And the median was 3.70.


Zydus Lifesciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Zydus Lifesciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Cyclically Adjusted Revenue per Share Chart

Zydus Lifesciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.50 130.47 144.19 157.54 171.08

Zydus Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 157.54 163.12 167.11 169.21 171.08

Competitive Comparison of Zydus Lifesciences's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Cyclically Adjusted PS Ratio falls into.


;
;

Zydus Lifesciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zydus Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=62.476/157.5517*157.5517
=62.476

Current CPI (Mar. 2025) = 157.5517.

Zydus Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 22.169 99.841 34.983
201509 22.139 101.753 34.279
201512 22.179 102.901 33.958
201603 22.335 102.518 34.325
201606 21.641 105.961 32.178
201609 22.816 105.961 33.925
201612 21.947 105.196 32.870
201703 23.444 105.196 35.112
201706 20.542 107.109 30.216
201709 30.723 109.021 44.399
201712 31.078 109.404 44.755
201803 29.984 109.786 43.029
201806 27.056 111.317 38.294
201809 27.794 115.142 38.031
201812 34.355 115.142 47.009
201903 35.394 118.202 47.177
201906 33.322 120.880 43.431
201909 31.776 123.175 40.644
201912 34.504 126.235 43.064
202003 35.362 124.705 44.676
202006 33.411 127.000 41.448
202009 35.177 130.118 42.594
202012 35.084 130.889 42.231
202103 34.259 131.771 40.962
202106 38.064 134.084 44.726
202109 35.781 135.847 41.498
202112 34.489 138.161 39.330
202203 36.552 138.822 41.484
202206 38.298 142.347 42.389
202209 38.860 144.661 42.323
202212 41.070 145.763 44.392
202303 47.959 146.865 51.449
202306 49.928 150.280 52.344
202309 42.070 151.492 43.753
202312 42.909 152.924 44.207
202403 53.070 153.035 54.636
202406 60.086 155.789 60.766
202409 50.844 157.882 50.738
202412 50.910 158.323 50.662
202503 62.476 157.552 62.476

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Zydus Lifesciences  (BOM:532321) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zydus Lifesciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=929.85/171.08
=5.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zydus Lifesciences was 7.98. The lowest was 2.07. And the median was 3.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zydus Lifesciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences Business Description

Industry
Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.

Zydus Lifesciences Headlines

No Headlines